NxStage Medical Says Single Needle Technology OneSite Obtains FDA Clearance

(RTTNews) - NxStage Medical Inc. (NXTM), a manufacturer of dialysis products, announced that its single needle technology, OneSite, has received the U.S. Food & Drug Administration or FDA clearance.

The OneSite employs a unique dual lumen needle design offered in both a sharp version with MasterGuard and a buttonhole version with SteriPick allowing the dialysis patient to have only one needle inserted per dialysis treatment instead of two. The combination of single site and buttonhole access is designed to provide patient comfort during needle insertion and dialysis treatment, as well as preservation of the patient's vascular access.

The dual lumen design also enhances patient safety during treatment by having the machine alarm and shutdown upon access dislodgement, reducing the risk of undetected Venous Needle Dislodgement or VND in the use of a two needle treatment.